Long
VBIV target [$3.50] by July 1st
Expect a significant appreciation in price leading up to the upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR virtual annual meeting.
Note
Large MACD divergence into what seems like price consolidation. Expecting a big move within the next 3-5 days. 
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.